Senestech (SNES) Stock News

SenesTech (NASDAQ: SNES), the manufacturer of EPA-registered rodent birth control products, reported strong Q2 2025 financial results. The company achieved record revenue of $625,000, up 36% year-over-year, with Evolve™ Rodent Birth Control products growing 94% and representing 83% of total revenue.

Key highlights include record gross profit margin of 65.4%, improved from 54.2% in Q2 2024, and a net loss of $1.6 million. The company maintains a strong cash position of $11.2 million as of August 5, 2025, providing runway through 2027. SenesTech expanded its municipal pilot deployments across major U.S. cities and completed a move to a new automated manufacturing facility in July 2025.

SenesTech (NASDAQ: SNES), a fertility control solutions provider for animal pest populations, has closed a warrant exercise transaction generating $6.3 million in gross proceeds. The transaction involved the exercise of existing warrants for 1,458,872 shares at $4.15 per share, with H.C. Wainwright acting as exclusive placement agent.

As part of the deal, SenesTech issued new unregistered short-term warrants to purchase 2,188,308 shares at $5.25 per share, with a purchase price of $0.125 per warrant. These new warrants, if fully exercised, could generate additional proceeds of $11.5 million. The company plans to use the net proceeds for working capital and general corporate purposes.

[ "Secured $6.3 million in immediate gross proceeds from warrant exercise", "Potential additional proceeds of $11.5 million if new warrants are fully exercised", "New warrants priced at $5.25, representing a 26.5% premium to previous warrant exercise price" ]

SenesTech (NASDAQ: SNES), a fertility control solutions provider for animal pest populations, has announced warrant exercise agreements that will generate $6.3 million in gross proceeds. The transaction involves the immediate exercise of existing warrants to purchase 1,458,872 shares at $4.15 per share.

As part of the deal, the company will issue new unregistered short-term warrants for 2,188,308 shares at an exercise price of $5.25 per share, with a purchase price of $0.125 per warrant. These new warrants will expire 15 months after the effective date of the resale registration statement. If fully exercised, the new warrants could generate additional proceeds of $11.5 million.

SenesTech (NASDAQ: SNES), a fertility control solutions provider for animal pest populations, has scheduled its Second Quarter 2025 financial results announcement for Thursday, August 7, 2025, after market close.

The company will host a conference call at 5:00 p.m. Eastern time on the same day to discuss the results. Investors can access the live webcast through the company's Investor Relations website, with a replay available for 90 days following the presentation.

SenesTech (NASDAQ: SNES), a fertility control solutions provider for animal pest populations, has announced the closing of a warrant exercise transaction that generated $4.4 million in gross proceeds. The transaction involved the exercise of existing warrants to purchase 1,458,872 shares of common stock at $2.90 per share.

As part of the transaction, the company issued new unregistered short-term warrants to purchase an additional 1,458,872 shares at $4.15 per share, with a purchase price of $0.125 per warrant. These new warrants expire 15 months after the effective date of the resale registration statement. If fully exercised, the new warrants could generate approximately $6.0 million in additional gross proceeds. H.C. Wainwright served as the exclusive placement agent for the transaction.

The company plans to use the net proceeds for working capital and general corporate purposes.

SenesTech (NASDAQ: SNES), a fertility control solutions provider for animal pest populations, has announced warrant exercise agreements that will generate $4.4 million in gross proceeds. The transaction involves the immediate exercise of existing warrants to purchase 1,458,872 shares of common stock at $2.90 per share, with an expected closing date of July 1, 2025.

As part of the transaction, SenesTech will issue new unregistered short-term warrants to purchase an additional 1,458,872 shares at $4.15 per share, with a purchase price of $0.125 per warrant. These new warrants will be exercisable immediately and expire fifteen months after the effective date of the resale registration statement. If fully exercised, these new warrants could generate additional gross proceeds of approximately $6.0 million.

The company plans to use the net proceeds for working capital and general corporate purposes. H.C. Wainwright is serving as the exclusive placement agent for the transaction.

SenesTech (NASDAQ: SNES) has reported successful results from major urban deployments of its Evolve™ Rat Birth Control solution in Hong Kong and San Francisco. The company's innovative approach combines fertility control with traditional rodenticide methods, demonstrating significant effectiveness in urban pest control.

In Hong Kong's high-density mixed-use building deployment, the company achieved dramatic reduction in rodent sightings and bait consumption within three months. Similar success was recorded in San Francisco, with notable decreases in rodent activity and new births. SenesTech is now preparing for a container-sized order from Hong Kong following these positive results.

SenesTech (NASDAQ: SNES) has successfully completed a nine-month field trial of Evolve™ Rat Birth Control at UC Irvine's University Hills residential community. The trial, conducted with Irvine Campus Housing Authority (ICHA), demonstrated 98% bait consumption across 267 stations, replacing traditional rodenticides with an eco-friendly solution.

The initiative, which began in September 2024, was driven by resident pressure to adopt safer pest management practices. The project supported the HOOT Group's efforts to promote owl nesting and reduce rodenticide use. Following the successful trial, ICHA is placing a multi-pallet restocking order for continued deployment and expansion.

SenesTech (NASDAQ: SNES) announced that Baltimore is expanding its deployment of Evolve™, the company's non-lethal rodent birth control product, following a successful pilot program. The city will implement Evolve™ more broadly in areas that showed measurable improvements during initial testing, integrating it into their existing pest management protocols. Evolve™, an EPA-classified minimum-risk pesticide, works by targeting rodent reproduction through a palatable soft bait that limits fertility in both male and female rodents. The product is designed to complement traditional pest control methods and poses no known risks to people, pets, or the environment when used as directed. Baltimore's pest control personnel reported enhanced results when incorporating Evolve™ into their existing protocols. SenesTech will provide ongoing support, including training and technical assistance throughout the rollout.